Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma

被引：59

作者：

Giles, FJ

Vose, JM

Do, KA

Johnson, MM

Manshouri, T

Bociek, G

Bierman, PJ

O'Brien, SM

Kantarjian, HM

Armitage, JO

Albitar, M

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Univ Nebraska, Med Ctr, Hematol Oncol Sect, Dept Internal Med, Omaha, NE 68182 USA

[3] Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA

[4] Univ Texas, MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA

来源：

LEUKEMIA RESEARCH | 2004年 / 28卷 / 06期

关键词：

Hodgkin's; lymphoma; VEGF; bFGF; HGF; angiogenin; prognosis; survival;

D O I：

10.1016/j.leukres.2003.11.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Vascular endothelial growth factor (VEGF), basic-fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), and angiogenin are important angiogenic factors. In 65 patients with non-Hodgkin's lymphoma (NHL), pre-treatment VEGF, bFGF, and HGF levels were significantly elevated compared to normal individuals, while angiogenin levels were significantly subnormal. In 37 patients with Hodgkin's disease, pre-treatment levels of VEGF and HGF were significantly elevated, bFGF levels were normal, and angiogenin levels were significantly subnormal. In patients with NHL, post-therapy levels of angiogenin were independently predictive of survival. Both pre-therapy and post-therapy VEGF levels were independently predictive of survival in patients with HID. (C) 2004 Published by Elsevier Ltd.

引用

收藏

页码：595 / 604

页数：10

相关论文

共 52 条

[1] Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes [J].

Aguayo, A ;

Kantarjian, H ;

Manshouri, T ;

Gidel, C ;

Estey, E ;

Thomas, D ;

Koller, C ;

Estrov, Z ;

O'Brien, S ;

Keating, M ;

Freireich, E ;

Albitar, M .

BLOOD, 2000, 96 (06) :2240-2245

[2] Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia [J].

Aguayo, A ;

Estey, E ;

Kantarjian, H ;

Mansouri, T ;

Gidel, C ;

Keating, M ;

Giles, F ;

Estrov, Z ;

Barlogie, B ;

Albitar, M .

BLOOD, 1999, 94 (11) :3717-3721

[3] Angiogenesis in acute myeloid leukemia and myelodysplastic syndrome [J].

Albitar, M .

ACTA HAEMATOLOGICA, 2001, 106 (04) :170-176

[4]

Badet J, 1999, PATHOL BIOL, V47, P345

[5] Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal [J].

Benjamin, LE ;

Keshet, E .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (16) :8761-8766

[6] Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma [J].

Bertolini, F ;

Paolucci, M ;

Peccatori, F ;

Cinieri, S ;

Agazzi, A ;

Ferrucci, PF ;

Cocorocchio, E ;

Goldhirsch, A ;

Martinelli, G .

BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (02) :504-509

[7] The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation [J].

Bierman, PJ ;

Lynch, JC ;

Bociek, RG ;

Whalen, VL ;

Kessinger, A ;

Vose, JM ;

Armitage, JO .

ANNALS OF ONCOLOGY, 2002, 13 (09) :1370-1377

[8] The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies [J].

Borset, M ;

Seidel, C ;

Hjorth-Hansen, H ;

Waage, A ;

Sundan, A .

LEUKEMIA & LYMPHOMA, 1999, 32 (3-4) :249-256

[9] Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia [J].

Brunner, B ;

Gunsilius, E ;

Schumacher, P ;

Zwierzina, H ;

Gastl, G ;

Stauder, R .

JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2002, 11 (01) :119-125

[10]

Cox D. R., 1984, Analysis of survival data

← 1 2 3 4 5 6 →